- Home
- MMU vs REPL Comparison
MMU vs REPL Comparison
Compare MMU & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MMU
- REPL
- Stock Information
- Founded
- MMU 1992
- REPL 2015
- Country
- MMU United States
- REPL United States
- Employees
- MMU N/A
- REPL N/A
- Industry
- MMU Investment Managers
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- MMU Finance
- REPL Health Care
- Exchange
- MMU Nasdaq
- REPL Nasdaq
- Market Cap
- MMU 568.0M
- REPL 547.0M
- IPO Year
- MMU N/A
- REPL 2018
- Fundamental
- Price
- MMU $10.33
- REPL $10.21
- Analyst Decision
- MMU
- REPL Buy
- Analyst Count
- MMU 0
- REPL 9
- Target Price
- MMU N/A
- REPL $10.88
- AVG Volume (30 Days)
- MMU 170.7K
- REPL 8.8M
- Earning Date
- MMU 01-01-0001
- REPL 11-07-2025
- Dividend Yield
- MMU 4.92%
- REPL N/A
- EPS Growth
- MMU N/A
- REPL N/A
- EPS
- MMU N/A
- REPL N/A
- Revenue
- MMU N/A
- REPL N/A
- Revenue This Year
- MMU N/A
- REPL N/A
- Revenue Next Year
- MMU N/A
- REPL N/A
- P/E Ratio
- MMU N/A
- REPL N/A
- Revenue Growth
- MMU N/A
- REPL N/A
- 52 Week Low
- MMU $8.60
- REPL $2.68
- 52 Week High
- MMU $10.45
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- MMU 46.72
- REPL 76.95
- Support Level
- MMU $10.40
- REPL $7.69
- Resistance Level
- MMU $10.45
- REPL $10.85
- Average True Range (ATR)
- MMU 0.06
- REPL 0.68
- MACD
- MMU -0.01
- REPL 0.54
- Stochastic Oscillator
- MMU 23.53
- REPL 90.24
About MMU Western Asset Managed Municipals Fund Inc.
Western Asset Managed Municipals Fd Inc is a non-diversified, closed-end management investment company. Its investment objective is to maximize current income exempted from federal income tax as is consistent with the preservation of principal. The fund predominantly invests in long-term investment grade municipal debt securities issued by state and local governments, political subdivisions, agencies, and public authorities (municipal obligations).
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.